Peter Chung | UHN Research

Dr. Peter Chung, MD

Claim this profile

University Health Network, Princess Margaret Hospital

Studies Prostate Cancer
Studies Testicular Cancer
9 reported clinical trials
16 drugs studied

Area of expertise

1

Prostate Cancer

Peter Chung, MD has run 5 trials for Prostate Cancer. Some of their research focus areas include:

Stage IV
Gleason
PSA
2

Testicular Cancer

Peter Chung, MD has run 1 trial for Testicular Cancer. Some of their research focus areas include:

Stage I
Stage II

Affiliated Hospitals

Image of trial facility.

University Health Network, Princess Margaret Hospital

Image of trial facility.

Princess Margaret Cancer Centre

Clinical Trials Peter Chung, MD is currently running

Image of trial facility.

Short vs Long Course Radiotherapy

for Prostate Cancer

This is a prospective, randomized phase II trial investigating if radiation treatment delivered every other day for 2 weeks has the same side effects as radiation treatment delivered once weekly for 6 weeks.

Recruiting

1 award

Phase 2

Image of trial facility.

MRI-Guided HDR Brachytherapy

for Prostate Cancer

This pilot study initiates a research program testing the early technical and clinical performance of a novel procedure for MRI-guided high-dose-rate (HDR) prostate brachytherapy. Testing will proceed in two cohorts of patients. In Arm 1, patients with locally recurrent prostate cancer after radiotherapy will receive tumor-targeted salvage HDR brachytherapy. Arm 1 of the study will be coordinated and closely integrated with a separate concurrent study of MRI-guided prostate biopsy, which will be performed prior to accrual to Arm 1 of this trial (UHN 05-0641-C). In arm 2, patients with locally advanced prostate cancer will receive a boost of prostate-targeted HDR brachytherapy during external beam radiotherapy. This technique will be prospectively evaluated in up to 500 patients. Preliminary data acquired in this pilot study will determine the technical limits of MRI guided HDR brachytherapy and will be critical for the judicious conduct of a subsequent phase II clinical trial. This proposal is innovative in two fundamental ways: MRI-guidance, and specific tumor targeting for HDR brachytherapy. Successful completion of this study will further individualize local therapy, not only for the benefit of the proportion of cancer patients for whom initial radiotherapeutic interventions have failed, but also provide valuable technical and clinical validation that these novel image-guided (IG) approaches are clinically feasible and could be applied more broadly in prostate cancer therapy.

Recruiting

1 award

N/A

More about Peter Chung, MD

Clinical Trial Related

13 years of experience running clinical trials · Led 9 trials as a Principal Investigator · 3 Active Clinical Trials

Treatments Peter Chung, MD has experience with

  • HDR Brachytherapy
  • MRI Guided Needles
  • High-Dose Rate (HDR) Radiotherapy
  • Volumetric Modulated Arc Therapy (VMAT)
  • Low-dose Computed Tomography (LDCT)
  • Postoperative Intensity Modulated Radiation Therapy

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?

What does Peter Chung, MD specialize in?

Is Peter Chung, MD currently recruiting for clinical trials?

Are there any treatments that Peter Chung, MD has studied deeply?

What is the best way to schedule an appointment with Peter Chung, MD?

What is the office address of Peter Chung, MD?

Is there any support for travel costs?